Biogen signs Factor VIII license agreement with Amunix

Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement with Amunix Operating to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Amunix will receive an upfront $1M payment and will also be eligible to receive up to $38M in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.

Advertisement